State Street’s ADC Therapeutics ADCT Stock Holding History

State Street’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.8M	Buy	1,685,836 +119,174	+8%	+$348K	﹤0.01%	3364
2026 Q1	$5.87M	Buy	1,566,662 +159,337	+11%	+$628K	﹤0.01%	2885
2025 Q4	$4.97M	Buy	1,407,325 +111,384	+9%	+$452K	﹤0.01%	2994
2025 Q3	$5.18M	Buy	1,295,941 +61,468	+5%	+$194K	﹤0.01%	2979
2025 Q2	$3.31M	Buy	1,234,473 +23,127	+2%	+$48.6K	﹤0.01%	3115
2025 Q1	$1.71M	Buy	1,211,346 +23,152	+2%	+$39.3K	﹤0.01%	3302
2024 Q4	$2.36M	Buy	1,188,194 +82,183	+7%	+$215K	﹤0.01%	3262
2024 Q3	$3.48M	Buy	1,106,011 +114,715	+12%	+$362K	﹤0.01%	3115
2024 Q2	$3.13M	Buy	+991,296	New	+$3.94M	﹤0.01%	3128
2022 Q3	–	Sell	-14,028	Closed	-$112K	–	4932
2022 Q2	$112K	Buy	+14,028	New	+$133K	﹤0.01%	4474

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street's ADCT Position: Q2 2026 in Review

State Street increased its ADC Therapeutics (ADCT) stake by 7.6% in Q2 2026, buying an estimated $348K and bringing the position to 1,685,836 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3364.

State Street first reported a position in ADCT in Q2 2022 and has held it in 10 quarters since. The position peaked at $5.87M in Q1 2026. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

State Street held 1,685,836 shares of ADC Therapeutics worth $1.8M as of Q2 2026.
State Street bought 119,174 ADC Therapeutics shares in Q2 2026, an estimated $348K.
ADC Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3364 holding.
State Street first reported a position in ADC Therapeutics in Q2 2022 and has held it in 10 quarters since.
State Street's ADC Therapeutics position peaked at $5.87M in Q1 2026.
114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.